Stonepine Capital Fully Exits ANI Pharmaceuticals, Reporting $2.52 Million Loss
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Dec 28 2025
0mins
Source: Yahoo Finance
- Full Exit: Stonepine Capital sold all 38,597 shares of ANI Pharmaceuticals in Q3, valued at approximately $2.52 million, marking a complete exit from the company as of September 30.
- Market Performance: Despite Stonepine's exit, ANI Pharmaceuticals' stock has risen 49% over the past year, currently priced at $82.41, significantly outperforming the S&P 500's 15% increase during the same period, indicating strong market competitiveness.
- Financial Growth: ANI Pharmaceuticals reported a 54% year-over-year revenue surge to $227.8 million in the latest quarter, with adjusted EBITDA jumping nearly 70% to $59.6 million, prompting management to raise full-year revenue guidance to $873 million.
- Investment Strategy Shift: The exit by Stonepine does not reflect a lack of confidence in ANI but rather a capital rotation, indicating a preference for earlier-stage biotech investments, which suggests a cautious outlook on ANI's future growth potential.
Get Free Real-Time Notifications for Any Stock
Monitor tickers like ANIP with instant alerts to capture every critical market movement.
Sign up for free to build your custom watchlist and receive professional-grade stock notifications.
Analyst Views on ANIP
Wall Street analysts forecast ANIP stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ANIP is 109.75 USD with a low forecast of 100.00 USD and a high forecast of 121.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
5 Analyst Rating
4 Buy
1 Hold
0 Sell
Strong Buy
Current: 79.510
Low
100.00
Averages
109.75
High
121.00
Current: 79.510
Low
100.00
Averages
109.75
High
121.00
About ANIP
ANI Pharmaceuticals, Inc. is a diversified biopharmaceutical company engaged in developing, manufacturing, and commercializing therapeutics. Its Rare Disease and Brands segment consists of two reporting units. The Rare Disease unit consists of operations related to the development, manufacturing, and marketing of branded pharmaceutical products, with a focus on products used in the treatment of patients with rare disease conditions and consists of operations related to Cortrophin Gel, ILUVIEN and YUTIQ. In addition, the Brands reporting unit includes a portfolio of over 16 brand products that are principally sold in genericized markets. Its Generics and Other segment consist of operations related to the development, manufacturing, and marketing of generic pharmaceutical products, including those sold through traditional wholesale and retail sales channels, sales of contract manufactured products, royalties on contract manufactured products, product development services, and others.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
S&P 500 Hits Record High as Data Storage Stocks Lead Gains
- Market Recovery: The S&P 500 index rose by 0.16% to reach a record high, while the Nasdaq 100 increased by 0.08% to a 2.25-month peak, indicating strong demand for data storage and chip manufacturing stocks.
- Surge in Metal Prices: Gold and silver prices soared to all-time highs, driving mining stocks higher, with Hecla Mining and Coeur Mining gaining over 8% and 5% respectively, reflecting strong investor interest in precious metals.
- Economic Data Focus: The market is set to focus on upcoming economic data releases, including December CPI and PPI, which are expected to influence future monetary policy amid political pressures on the Federal Reserve.
- Earnings Season Kickoff: S&P 500 companies are projected to see an 8.4% earnings growth in Q4, while excluding the Magnificent Seven tech giants, earnings growth is expected at 4.6%, providing crucial signals for investors.
Continue Reading
Trump Pressures Fed, Credit Card Stocks Slide Amid Legal Threats
- Market Volatility: The S&P 500 Index rose by 0.28%, the Dow Jones Industrial Average increased by 0.15%, and the Nasdaq 100 climbed by 0.55%, despite heightened concerns over Fed independence due to the Trump administration's attacks, leading to a 'Sell America' sentiment in US asset markets.
- Credit Card Companies Hit: President Trump stated that credit card lenders would be 'in violation of the law' if they do not cap interest rates at 10% for one year, causing significant declines in credit card and bank stocks, with Synchrony Financial down over 7% and Capital One Financial down over 6%.
- Gold Prices Surge: Gold and silver prices soared to new all-time highs, driving mining stocks higher, with Hecla Mining up over 8% and Coeur Mining up over 6%, reflecting strong investor demand for safe-haven assets amid market uncertainty.
- Fed Faces Legal Threats: Fed Chair Powell indicated that the threat of criminal charges stems from the Fed's refusal to comply with Trump's calls for lower interest rates, which could impact future policy decisions and create greater uncertainty in market expectations regarding interest rate movements.
Continue Reading